NASDAQ:VRDN Viridian Therapeutics Q1 2025 Earnings Results & Report $30.06 +0.26 (+0.87%) Closing price 04:00 PM EasternExtended Trading$30.06 0.00 (-0.02%) As of 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Viridian Therapeutics beat analyst earnings expectations but missed on revenue in its Q1 2025 results, released May 6, 2025. The company reported EPS of -$0.87 versus the -$0.95 consensus estimate, while revenue of $70 thousand fell short of the $160 thousand estimate by $90 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 6, 2025TimeBefore Market OpensConference Call7:00 AM ET Viridian Therapeutics EPS ResultsActual EPS-$0.87Consensus EPS -$0.95Beat/MissBeat by +$0.08One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersViridian Therapeutics Revenue ResultsActual Revenue$70 thousandExpected Revenue$160 thousandBeat/MissMissed by -$90.00 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Viridian Therapeutics Q1 2025 Earnings FAQ Did Viridian Therapeutics beat earnings estimates for Q1 2025? Viridian Therapeutics (NASDAQ:VRDN) reported earnings of -$0.87 per share for Q1 2025, beating the consensus estimate of -$0.95. The report was announced on Tuesday, May 6, 2025. What was Viridian Therapeutics' revenue for Q1 2025? Viridian Therapeutics reported revenue of $70 thousand for Q1 2025, against a consensus estimate of $160 thousand. Viridian Therapeutics Earnings HeadlinesViridian Therapeutics, Inc. (VRDN) Discusses VRDN-008 Phase I Results and FcRn Portfolio Development Plans - SlideshowNovember 13, 2026 | seekingalpha.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Viridian Therapeutics (VRDN), Editas Medicine (EDIT) and Praxis Precision Medicines (PRAX)November 12, 2026 | theglobeandmail.comLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, protect it. This report normally sells for $29.97, but it's available as a free download for a limited time.November 17 at 1:00 AM | Profits Run (Ad)Viridian Therapeutics: FcRn Pipeline Takes Shape After VRDN-008 Phase 1 ResultsNovember 10, 2026 | seekingalpha.comWedbush Adjusts Price Target on Viridian Therapeutics to $44 From $42, Maintains Outperform RatingNovember 9, 2026 | marketscreener.comMViridian Therapeutics gains long-term potential from extended-acting FcRn drug, Jefferies saysNovember 9, 2026 | finance.yahoo.comSee More Viridian Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Viridian Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Viridian Therapeutics and other key companies, straight to your email. Email Address About Viridian TherapeuticsViridian Therapeutics (NASDAQ:VRDN) is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a primary focus on thyroid eye disease (TED), an autoimmune condition that can cause inflammation and changes around the eyes. The company’s pipeline includes veligrotug, an investigational antibody that targets the insulin-like growth factor 1 receptor, a pathway involved in TED. Viridian is also developing additional antibody-based candidates intended to offer treatment options, including formulations designed for under-the-skin administration. These candidates remain investigational. Viridian’s roots include Miragen Therapeutics, which adopted the Viridian Therapeutics name in 2021. The company conducts clinical development to evaluate its potential treatments; its candidates are not approved medicines.View Viridian Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.